Share-based Payment Arrangement, Expense of AbCellera Biologics Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AbCellera Biologics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • AbCellera Biologics Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $12,904,000, a 15% decline year-over-year.
  • AbCellera Biologics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $55,792,000, a 17% decline year-over-year.
  • AbCellera Biologics Inc. annual Share-based Payment Arrangement, Expense for 2025 was $55,792,000, a 17% decline from 2024.
  • AbCellera Biologics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $67,581,000, a 5.3% increase from 2023.
  • AbCellera Biologics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $64,184,000, a 30% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AbCellera Biologics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $55,792,000 $12,904,000 -$2,322,000 -15% 01 Oct 2025 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q3 2025 $58,114,000 $13,894,000 -$3,270,000 -19% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $61,384,000 $14,208,000 -$3,574,000 -20% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $64,958,000 $14,786,000 -$2,623,000 -15% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $67,581,000 $15,226,000 -$1,223,000 -7.4% 01 Oct 2024 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q3 2024 $68,804,000 $17,164,000 +$1,302,000 +8.2% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $67,502,000 $17,782,000 +$1,383,000 +8.4% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $66,119,000 $17,409,000 +$1,935,000 +13% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $64,184,000 $16,449,000 +$3,126,000 +23% 01 Oct 2023 31 Dec 2023 10-K 24 Feb 2026 2025 FY
Q3 2023 $61,058,000 $15,862,000 +$4,108,000 +35% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $56,950,000 $16,399,000 +$4,286,000 +35% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $52,664,000 $15,474,000 +$3,183,000 +26% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $49,481,000 $13,323,000 +$4,284,000 +47% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $45,197,000 $11,754,000 +$4,047,000 +53% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $41,150,000 $12,113,000 +$3,640,000 +43% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $37,510,000 $12,291,000 +$6,864,000 +126% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $30,646,000 $9,039,000 +$4,418,000 +96% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 $26,228,000 $7,707,000 +$5,774,000 +299% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $20,454,000 $8,473,000 +$7,867,000 +1298% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $12,587,000 $5,427,000 +$4,190,000 +339% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $8,397,000 $4,621,000 01 Oct 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
Q3 2020 $1,933,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $606,000 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $1,237,000 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1

AbCellera Biologics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $55,792,000 -$11,789,000 -17% 01 Jan 2025 31 Dec 2025 10-K 24 Feb 2026 2025 FY
2024 $67,581,000 +$3,397,000 +5.3% 01 Jan 2024 31 Dec 2024 10-K 24 Feb 2026 2025 FY
2023 $64,184,000 +$14,703,000 +30% 01 Jan 2023 31 Dec 2023 10-K 24 Feb 2026 2025 FY
2022 $49,481,000 +$18,835,000 +61% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $30,646,000 +$22,249,000 +265% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $8,397,000 +$7,507,000 +843% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 $890,000 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.